Despite this potential for complex mechanism of action, lenabasum is particularly notable as the most thoroughly characterised CB2-active compound in human trials to date, including in diseases likely involving macrophage dysregulation, cystic fibrosis, systemic sclerosis (SSc), and dermatomyositis. Here, CNR2 is linked to systemic sclerosis.